Schroder Investment Management Group Boosts Stake in Vera Therapeutics

Institutional investor increases position in biotech firm by 82.4% in Q3

Mar. 13, 2026 at 9:36am

Got story updates? Submit your updates here. ›

Schroder Investment Management Group has significantly increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing novel immunotherapies. According to a recent SEC filing, the institutional investor added 307,243 shares during the third quarter, bringing its total ownership to 679,992 shares or approximately 1.07% of the company's outstanding stock.

Why it matters

The substantial increase in Schroder's position suggests the investment firm sees significant potential in Vera Therapeutics' pipeline of autoimmune and inflammatory disease treatments. As a major institutional investor, Schroder's vote of confidence could signal growing market enthusiasm for the company's novel therapeutic approach.

The details

Schroder Investment Management Group lifted its position in Vera Therapeutics by acquiring an additional 307,243 shares during the third quarter. This represents an 82.4% increase in the firm's existing stake, bringing its total ownership to 679,992 shares valued at $19.65 million as of the end of the reporting period.

  • Schroder Investment Management Group increased its position in Vera Therapeutics during the 3rd quarter of 2026.

The players

Schroder Investment Management Group

A global asset management firm that provides investment management products and services to institutional and retail clients worldwide.

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies to treat autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

Schroder Investment Management Group's substantial increase in its Vera Therapeutics stake suggests the firm sees significant long-term potential in the biotech company's pipeline of innovative immunotherapies. This vote of confidence from a major institutional investor could signal growing market enthusiasm for Vera Therapeutics' unique approach to treating autoimmune and inflammatory disorders.